SoftBank Group launches AI healthcare joint venture with Tempus

SoftBank Group has launched a joint venture called ‘SB TEMPUS Corp.’ with Tempus AI, a leader in AI and precision medicine. The joint venture aims to provide precision medicine services in Japan by applying the expertise and technology that Tempus has accumulated in the US. That includes Tempus’ AI-enabled platform, which works to make diagnostics more intelligent and support healthcare providers in making more informed decisions. The goal is to provide personalised, data-driven therapies to patients, with the aim of helping them live longer and healthier lives.

A key focus of the joint venture will be collecting and analysing siloed and unstructured medical data, such as molecular, clinical, pathological, and medical imaging data. By leveraging AI to analyse this data, the joint venture aims to contribute to the advancement of pharmaceutical research, including clinical and drug discovery research and the proposal of treatment plans more suited to individual patients. That approach is expected to reduce side effects and enhance the effectiveness of medications, marking a significant step towards personalised medicine.

To help as many people suffering from cancer as possible, SB TEMPUS plans to establish collaborations with cancer genomic medicine hospitals and Japanese hospitals, medical facilities, pharmaceutical companies, biotech ventures, medical device companies, cancer insurance companies, and testing companies.

Why does it matter?

The collaborative network will support the provision of better diagnosis and treatment for patients, ensuring that they benefit from personalised, data-driven therapies. Also, the joint venture aligns with SoftBank’s corporate philosophy of ‘Information Revolution—Happiness for everyone.’